German Pharma Wants Inflation-Linked Deal To Replace Drug Price Freeze
This article was originally published in The Pink Sheet Daily
With the German drug price freeze set to continue, the pharmaceutical industry wants to see at least an inflation-linked rise in prices and the abandonment of HTA for older products.
You may also be interested in...
Germany’s pharmaceutical sector reforms represent a mixed bag for industry, with the price freeze set to continue, while rebate levels to health insurers are slashed.
CHMP has released for the first time the minutes of its meeting, and EMA has set up a new pharmacovigilance cluster with the FDA. A biosimilar infliximab product from Hospira and Alvogen has become the first biosimilar monoclonal antibody launched in Europe.
Germany’s senior reimbursement body, the G-BA, has announced it will assess a second wave of older drugs, despite a pending coalition agreement dropping this practice.